Valneva SE Sponsored ADR (NASDAQ:VALN) Receives Consensus Rating of “Hold” from Brokerages

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have been given an average rating of “Hold” by the five brokerages that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $11.9750.

A number of brokerages have commented on VALN. The Goldman Sachs Group cut shares of Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target on the stock. in a research report on Wednesday, April 22nd. Guggenheim set a $11.00 price target on shares of Valneva in a research report on Thursday, April 16th. Finally, Wall Street Zen upgraded shares of Valneva from a “strong sell” rating to a “sell” rating in a report on Saturday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VALN. China Universal Asset Management Co. Ltd. purchased a new stake in Valneva in the fourth quarter worth $44,000. VSM Wealth Advisory LLC lifted its stake in Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock worth $110,000 after acquiring an additional 5,000 shares during the period. JPMorgan Chase & Co. purchased a new stake in Valneva in the third quarter worth $124,000. XTX Topco Ltd purchased a new stake in Valneva in the fourth quarter worth $94,000. Finally, Marex Group plc purchased a new stake in Valneva in the second quarter worth $64,000. Institutional investors own 11.39% of the company’s stock.

Valneva Trading Down 4.4%

Shares of Valneva stock opened at $5.68 on Friday. Valneva has a 12-month low of $5.06 and a 12-month high of $12.25. The company has a market cap of $489.10 million, a price-to-earnings ratio of -3.04 and a beta of 1.72. The company has a current ratio of 2.14, a quick ratio of 1.85 and a debt-to-equity ratio of 2.14. The company’s 50-day moving average price is $7.08 and its 200-day moving average price is $8.59.

Valneva (NASDAQ:VALN) last announced its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The company had revenue of $35.77 million during the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. On average, equities analysts expect that Valneva will post -0.81 earnings per share for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.